Clinical Trial Update: A Study of ATG-018 (ATR Inhibitor) Treatment in Patients With Advanced Solid Tumors and Hematological Malignancies [Phase 1]

View source ↗

Summary

Phase 1 study of ATG-018, an ATR inhibitor, in patients with advanced solid tumors and hematological malignancies has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hematological Malignancies
• Solid Tumors

Drugs mentioned

• ATG-018 (ATR inhibitor)

Snippet

Sponsor: Antengene Discovery Limited | Conditions: Advanced Solid Tumors, Hematological Malignancies | Phase 1 | Status: TERMINATED